Interfarma in the Brazilian Market
Our members have accounted for at least half of the domestic pharmaceutical market for over ten years. From 2017 to 2021, the average percentage of participation was 46% (Interfarma Guide 2022), according to turnover published in commercial reports for the pharmaceutical industry.
Patient Support Programs (PSPs) are another way of expanding and improving access to drugs and treatments in Brazil. According to data from the 2020 Sustainability Report, in 2019, 68% of companies (21 of the 31 that responded) have programs of
this type and 90% of them adopt practices that allow patient satisfaction evaluation regarding service within the program. Twelve associates invested R$ 4.6 million and more than 10 million people benefitted from these programs.
In addition to this, research and innovation are in the DNA of the pharmaceutical industry. In 2019, the amount invested by 19 associates was US$ 80.1 billion worldwide. In Brazil, 12 associates invested R$ 657 million. There were 483 molecule
development programs and projects (pre-clinical research and clinical research) by 15 associates and 183 clinical studies, with investments of more than R$ 573.4 million, in Brazil.
Through our associates, we also contribute to campaigns on the correct use of drugs, the importance of vaccination, among others. In 2019, 77% of companies had structured educational programs, geared towards health professionals, for example. In
all, 105,951 health professionals were reached with initiatives carried out in the year.
Data from 2019 reflect the years of efforts made by companies for more diversity, mainly concerning gender. From 2017 to 2019, there was a significant growth, with 49% of employees being men and 51% women, whereas in 2017, 57% were men and
43% women. Also, according to the 2020 Sustainability Report, taking into account the companies who replied, 37% of the Administrative Council were women, and 3% were black. In leadership positions, considering coordination level and above, there was an increase in female participation. In 2019, women accounted for 52% of leadership positions, as against 23% in 2017.